Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFD-200 in Healthy Participants and Rheumatoid Arthritis
NCT07207954Phase 1Recruiting
- Sponsor
- Lifordi Immunotherapeutics
- Start
- Oct 2025
- Primary completion
- Jul 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of LFD-200 in rheumatoid arthritis (RA) (3 arms), sponsored by Lifordi Immunotherapeutics. Primary endpoints: Incidence of Adverse Events, Severity of Adverse Events and 14 more. Started Oct 2025; status: recruiting.
02
Drugs
LFD-200
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07207954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207954.